Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;116:2687-2693
Published online before print November 19, 2007, doi: 10.1161/CIRCULATIONAHA.107.723270
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
116/23/2687    most recent
CIRCULATIONAHA.107.723270v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Solomon, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Solomon, S. D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*End of Life Issues
*Kidney Diseases
Related Collections
Right arrow Chronic ischemic heart disease

(Circulation. 2007;116:2687-2693.)
© 2007 American Heart Association, Inc.


Coronary Heart Disease

Influence of Albuminuria on Cardiovascular Risk in Patients With Stable Coronary Artery Disease

Scott D. Solomon, MD*; Julie Lin, MD, MPH*; Caren G. Solomon, MD, MPH; Kathleen A. Jablonski, PhD; Madeline Murguia Rice, PhD; Michael Steffes, MD; Michael Domanski, MD; Judith Hsia, MD; Bernard J. Gersh, MBChB, DPhil; J. Malcolm O. Arnold, MD; Jean Rouleau, MD; Eugene Braunwald, MD; Marc A. Pfeffer, MD, PhD, for the Prevention of Events With ACE Inhibition (PEACE) Investigators

From the Divisions of Cardiovascular Medicine, Renal Medicine, and General Medicine, Brigham and Women’s Hospital (S.D.S., J.L., C.G.S., E.B., M.A.P.), Boston, Mass; George Washington University Biostatistics Center (K.A.J., M.M.R., J.H.), Rockville, Md; University of Minnesota Medical Center (M.S.), Minneapolis, Minn; National Heart, Lung, and Blood Institute (M.D.), Bethesda, Md; Mayo Clinic College of Medicine (B.J.G.), Rochester, Minn; London Health Sciences Centre, (J.M.O.A.), London, Ontario, Canada; and University of Montreal (J.R.), Montreal, Quebec, Canada.

Correspondence to Scott D. Solomon, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail ssolomon{at}rics.bwh.harvard.edu

Received June 22, 2007; accepted September 27, 2007.

Background— Patients with chronic kidney disease are at increased risk for cardiovascular morbidity and mortality. We assessed the association between albuminuria and the risks for death and cardiovascular events among patients with stable coronary disease.

Methods and Results— We studied patients enrolled in the Prevention of Events with an ACE inhibitor (PEACE) trial, in which patients with chronic stable coronary disease and preserved systolic function were randomized to trandolapril or placebo and followed up for a median of 4.8 years. The urinary albumin to creatinine ratio (ACR) assessed in a core laboratory in 2977 patients at baseline and in 1339 patients at follow-up (mean 34 months) was related to estimated glomerular filtration rate and outcomes. The majority of patients (73%) had a baseline ACR within the normal range (<17 µg/mg for men and <25 µg/mg for women). Independent of the estimated glomerular filtration rate and other baseline covariates, a higher ACR, even within the normal range, was associated with increased risks for all-cause mortality (P<0.001) and cardiovascular death (P=0.01). The effect of trandolapril therapy on outcomes was not modified significantly by the level of albuminuria. Nevertheless, trandolapril therapy was associated with a significantly lower mean follow-up ACR (12.5 versus 14.6 µg/mg, P=0.0002), after adjustment for baseline ACR, time between collections, and other covariates. An increase in ACR over time was associated with increased risk of cardiovascular death (hazard ratio per log ACR 1.74, 95% CI 1.08 to 2.82).

Conclusions— Albuminuria, even in low levels within the normal range, is an independent predictor of cardiovascular and all-cause mortality.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
DiabetesHome page
P.-H. Groop, M. C. Thomas, J. L. Moran, J. Waden, L. M. Thorn, V.-P. Makinen, M. Rosengard-Barlund, M. Saraheimo, K. Hietala, O. Heikkila, et al.
The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes
Diabetes, July 1, 2009; 58(7): 1651 - 1658.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. Sanz, P. R. Moreno, and V. Fuster
The year in atherothrombosis.
J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1326 - 1337.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
J. Danziger
Importance of Low-Grade Albuminuria
Mayo Clin. Proc., July 1, 2008; 83(7): 806 - 812.
[Abstract] [Full Text] [PDF]